Theravance Biopharma, Inc. (TBPH)
NASDAQ: TBPH · Real-Time Price · USD
9.23
-0.08 (-0.86%)
Mar 28, 2025, 4:00 PM EDT - Market closed
Theravance Biopharma Revenue
In the year 2024, Theravance Biopharma had annual revenue of $64.38M with 12.12% growth. Theravance Biopharma had revenue of $18.75M in the quarter ending December 31, 2024, with 6.77% growth.
Revenue (ttm)
$64.38M
Revenue Growth
+12.12%
P/S Ratio
7.00
Revenue / Employee
$663,722
Employees
97
Market Cap
456.61M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 64.38M | 6.96M | 12.12% |
Dec 31, 2023 | 57.42M | 6.08M | 11.84% |
Dec 31, 2022 | 51.35M | -3.97M | -7.17% |
Dec 31, 2021 | 55.31M | -16.55M | -23.03% |
Dec 31, 2020 | 71.86M | -1.56M | -2.12% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
TBPH News
- 1 day ago - Theravance Biopharma to Present New Ampreloxetine Analyses in Neurogenic Orthostatic Hypotension (nOH) at the 77th Annual Meeting of the American Academy of Neurology - PRNewsWire
- 4 weeks ago - Theravance Biopharma, Inc. (TBPH) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Theravance Biopharma, Inc. Reports Record Fourth Quarter and Full Year 2024 Financial Results - PRNewsWire
- 5 weeks ago - Theravance Biopharma to Participate in an Upcoming Investor Conference - PRNewsWire
- 6 weeks ago - Theravance Biopharma to Report Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025 - PRNewsWire
- 3 months ago - Theravance Biopharma to Conduct Investor Meetings During the J.P. Morgan 43rd Annual Healthcare Conference - PRNewsWire
- 4 months ago - Theravance Biopharma, Inc. (TBPH) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 4 months ago - Theravance Biopharma, Inc. Reports Third Quarter 2024 Financial Results and Announces Initiatives to Unlock Shareholder Value - PRNewsWire